+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Excess costs associated with patients with chronic thromboembolic pulmonary hypertension in a US privately insured population



Excess costs associated with patients with chronic thromboembolic pulmonary hypertension in a US privately insured population



Applied Health Economics and Health Policy 9(6): 377-387



Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare and potentially fatal disease. Little is known about the economic burden associated with CTEPH patients in the US. The objective of this study was to estimate excess direct costs associated with privately insured patients with CTEPH in the US. From a privately insured claims database (>8 million beneficiaries, 2002-7), 289 CTEPH patients were identified using the criteria: two or more claims for pulmonary hypertension (PH), International Classification of Diseases, ninth edition, clinical modification (ICD-9-CM) code 416.0 or 416.8; one or more claim for pulmonary embolism (ICD-9-CM: 415.1, V12.51; ICD-9 procedure: 38.7; Current Procedural Terminology [CPT]-4 code: 36010, 37620, 75825, 75940; Healthcare Common Procedure Coding System [HCPCS] code: C1880) within 12 months prior or 1 month after the initial PH claim (index date); one or more claim for right heart catheterization (RHC) within 6 months prior to any PH claim or one or more claim for echocardiogram within 6 months prior to a specialist-diagnosed PH claim; aged 18-64 years. Patients with CTEPH were matched demographically to controls without PH. Patients were followed as long as continuously eligible; mean follow-up in CTEPH patients was 21.5 months. Chi-squared tests were used to compare baseline co-morbidities. Wilcoxon rank-sum tests were used to compare direct (medical and pharmaceutical) patient-month costs to insurers. The average age for CTEPH patients was 52.2 years, and 57.1% were women. Compared with controls, CTEPH patients had significantly higher baseline rates of co-morbidities (e.g. essential hypertension, congestive heart failure and chronic pulmonary disease) and a higher mean Charlson Co-morbidity Index score. Mean direct patient-month costs (year 2007 values) were $US4782 for CTEPH patients and $US511 for controls (p < 0.0001). Sensitivity analysis restricting the sample to patients diagnosed following RHC yielded a 15% increase in excess costs relative to the original sample. Regarding cost drivers, inpatient services accounted for 54%, outpatient and other services for 33% and prescription drugs for 11% of total direct healthcare costs per patient-month in CTEPH patients. Circulatory-/respiratory-related patient-month costs were $US2496 among CTEPH patients and $US128 among controls (p < 0.0001). CTEPH patients had substantially higher costs and co-morbidity than matched controls, with circulatory-/respiratory-related costs accounting for 55% of excess costs. The high burden of illness suggests opportunities for savings from improved management.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 053112598

Download citation: RISBibTeXText

PMID: 21888449

DOI: 10.2165/11592440-000000000-00000


Related references

Excess costs associated with patients with pulmonary arterial hypertension in a US privately insured population. Applied Health Economics and Health Policy 9(5): 293-303, 2011

Healthcare and workloss costs associated with patients with persistent asthma in a privately insured population. Journal of Occupational and Environmental Medicine 48(8): 794-802, 2006

Direct health care costs of patients with type 2 diabetes within a privately insured employed population, 2000 and 2005. Journal of Occupational and Environmental Medicine 51(12): 1460-1465, 2009

Population pharmacokinetics and the pharmacokinetic/pharmacodynamic relationship of riociguat in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension. Pulmonary Circulation 6(Suppl 1): S86-S96, 2016

Costs of Parkinsona s Disease in a Privately Insured Population. 2013

Costs of Parkinson's disease in a privately insured population. Pharmacoeconomics 31(9): 799-806, 2013

Children with orofacial clefts: health-care use and costs among a privately insured population. Public Health Reports 124(3): 447-453, 2009

Medical care costs of Paget's disease of bone in a privately insured population. Bone 38(5): 731-737, 2005

Patterns of mental health utilization and costs among children in a privately insured population. Health Services Research 36(1 Pt 1): 113-127, 2001

Characterizing pulmonary hypertension-related hospitalization costs among Medicare Advantage or commercially insured patients with pulmonary arterial hypertension: a retrospective database study. American Journal of Managed Care 21(3 Suppl): S47-S58, 2015

Changes in inpatient mental health utilization and costs in a privately insured population, 1993 to 1995. Medical Care 37(5): 457-468, 1999

Treatment for substance use disorders in a privately insured population under managed care: costs and services use. Journal of Substance Abuse Treatment 27(4): 265-275, 2004

Bosentan therapy for chronic thromboembolic pulmonary hypertension. A national open label study assessing the effect of Bosentan on haemodynamics, exercise capacity, quality of life, safety and tolerability in patients with chronic thromboembolic pulmonary hypertension (BOCTEPH-Study). Swiss Medical Weekly 137(41-42): 573-580, 2007

Direct and indirect healthcare resource utilization and costs associated with ulcerative colitis in a privately-insured employed population in the US. Journal of Medical Economics 18(6): 447-456, 2015

Healthcare costs and utilization for privately insured patients treated for non-infectious uveitis in the USA. Journal of Ophthalmic Inflammation and Infection 3(1): 64, 2013